List of Vendor Companies in Italy - 29

Adaltis S.r.l. is an international IVD company headquartered in Rome, Italy. Adaltis develops, manufactures and markets in-vitro diagnostic systems and reagents to detect viral infections, diagnose immune system diseases and measure human hormone responses. http://www.adaltis.net/products/ Personal LAB - fully automated 2 plate microELISA/IFA analyser NEXgen - fully automated 7 plate microELISA / IFA analyser EXTRAlab - Robotic systems for liquid handling, extraction/purification of nucleic acids Pchem Family - clinical chemistry systems for 120-500 tests/hour (Instruments and dedicated reagents). HEMO One - Point of Care Analyser (Diabetes / Vitamin deficiencies / Metabolic disorders / Inflammatory diseases) With more than 10 thousands of instruments installed worldwide, Adaltis is known for excellence in performance and innovation. Adaltis' development and production of reagents include a wide range of assays: - Diagnostic kits for detection of infection agents by real-time PCR (MOLgen Line) - MicroELISA kits (EIAgen) - Clinical Chemistry / Turbidity / Latex (CHEMgen) - Genomics & Bioinformatics MDx kits and reagents for DNA/RNA complete extraction kits providing a wide range of clinical specimens (liquids, tissue, cells etc.), compatible with most DNA extraction kits on market. Adaltis provides: Dedicated Customized Services and Antibody Production. Adaltis has a strong record in OEM / ODM development and production of systems and kits. Well known partners have experienced and enjoy the expertise and quality products of Adaltis. Adaltis is ISO 9001 and ISO 13485 certified. Our products are IVD-CE marked. All of our products are backed by dedicated application support and technical service. Customer Care Center: info@adaltis.net Sales and Marketing Office: sales@adaltis.net Order Handling and Logistics: order@adaltis.net Tel: + 39 0774 5791

Allelica is a software and research company democratizing access to clinical-grade Polygenic Risk Score. Allelica is the first Company to have developed a Software as a Service and on-premise infrastructure to allow clinical genetics labs and biopharma companies to perform Polygenic Risk Score analysis in multiple ancestries. Our research work has been published in the American Heart Association Journal, Circulation and presented in the most prestigious conferences in genomics (ASHG) and cardiology (ESC). Our mission is to reduce human suffering making better medicine. We believe in a data-driven primary prevention, able to detect high risk individuals who benefit from personalised prevention and screening plans. www.allelica.com

Anemocyte is an Italian Biotech Manufacturing Organization with a strong focus on the development, manufacturing, and analytical services to address needs in the field of: • pDNA – Plasmids manufacturing (R&D, Hiqh-Quality, and GMP) for Viral Vector and mRNA; • mRNA – mRNA manufacturing (R&D) for vaccines and therapeutic treatments. Our experience: • More than 20 years of development and manufacturing experience (from R&D to GMP) in the field of Cell and Gene Therapies and Nucleic Acids. • Over the years, Anemocyte has been involved in multiple projects with a wide range of complexity.

Avantea is a laboratory of advanced technologies for biotechnology research and animal reproduction. The activity of this laboratory began in 1991 with Cesare Galli and Giovanna Lazzari. In 2008 it became Avantea Srl, inheriting all the skills and expertise built in about twenty years of activity and the know-how developed through years of research conducted in the biomedical and animal reproduction fields. Credibility and experience make Avantea a reliable and highly specialized center, which aims to find innovative solutions in the field of reproductive biotechnology for livestock breeding and biomedicine. Avantea research activity is assessed by an independent Ethics Committee, which includes leading experts in animal health and welfare, bioethics, genetics, law and forensic medicine and it is in agreement with the guidelines for the application of Article 48 of the Ethics Code of the National Federation of Italian Veterinarians. Avantea has a Quality Management System and obtained the Quality Certification according to UNI EN 9001:2008.

Axxam is a leading provider of integrated discovery services across the life sciences industry with headquarters in Milan, Italy. Within the drug discovery disciplines, we support pharma, biotech companies, start-ups, patient foundations as well as academic groups in their journey from hit identification to lead generation, regardless of the therapeutic area and target class. Our services include assay development, high-throughput screening, using either Axxam's high quality compound collections (synthetic and natural) or those provided by clients, hit validation and compound management. The same science-driven approach is also applied to identify new bioactive compounds for crop protection, animal health, food, beverage, pet food, cosmetic and perfume industries.

Bioscience Institute is a cell factory dedicated to biological cryopreservation, cell culture and scientific research. The Bioscience Institute laboratories engage in the extraction, analysis, expansion and planned freezing of several cell types. The cryopreservation room, on the other hand, is used for storage of the stem cells extracted from the blood in the umbilical cord, from the adipose tissue and mature cells such as fibroblasts, melanocytes and keratinocytes. in collaboration with prestigious Italian and foreign universities, Bioscience Institute deals with scientific research work whose aim is to extend the possible clinical applications of stem cells to various areas of medicine: cardiology, surgery, neurology, gynaecology and dermatology.

Driven by our mission to advance research and improve lives, BMR Genomics serves as a trusted partner for both academic and commercial projects in the life sciences. BMR Genomics, a spin-off of the University of Padua, initially focused on providing DNA analysis to universities and research centers. BMR has grown into a leading provider of comprehensive genomics services for researchers, companies, and private individuals across the life sciences sector. In 2008, we were honored with the award for Italy's best start-up. At BMR Genomics, we offer a broad range of advanced services, including DNA sequencing (Sanger, Illumina, and Oxford Nanopore), cell authentication (Cell Profile), DNA genotyping, and bioinformatics support. Additionally, we supply life science lab products through Easy Shop and custom oligonucleotides through Custom Primer. We also cater to private individuals and professionals by providing human identification, paternity, and relative testing. Our expertise spans diverse areas such as medical diagnostics, microbiology, agriculture, veterinary science, and environmental research. With cutting-edge laboratories and a commitment to staying at the forefront of genomics and bioinformatics, we continually innovate to meet the evolving needs of the scientific community. For more information, contact us at commerciale@bmr-genomics.it.

Manufacturer of APIs Certifications - FDA inspected since 2004. Last FDA Inspection Aug 2011 - cGMP compliance - Authorized by Brazilian Ministry of Health - Filed accreditation JP PMDA .

Comecer, an ATS company, develops and manufactures high-tech systems for Aseptic Processing and Containment in Pharmaceutical and Nuclear Medicine Industries, specialising in isolation technology solutions for regenerative medicine and tissue engineering. We develop highly innovative technologies and sustainable solutions, according to the latest GMP (Good Manufacturing Practice) regulations. The ability to build tailor-made solutions for our clients has been vital to our success. We operate in industries where each client has unique requirements, so standard solutions in most cases are not a good fit. That's why we always start new projects by listening to client needs and requirements. We assign a dedicated project team that analyses and understands the processes and the environment since no two organizations have identical characteristics. This team collects all the data, studies all aspects and designs solutions. This is where years of experience come into play. We then discuss with the client the possible alternatives that can meet their requirements. Many customers are not aware of how much customization is possible and our proposals surprise them. Containment: isolators to handle highly active principles or excipients (ATEX, where required), isolators to load reactors, multi-stage isolators for chemical synthesis or laboratory operations. Asepsis: isolators for sterility tests and formulation of sterile drugs, isolators/RABs integrated into the liquid or powder filling lines, dedicated solutions for Regenerative Medicine applications. Grade A pharmaceutical continuity: RABs, laminar flow trolleys, transfer hatch (with VPHP, where required). We also operate in the field of nuclear medicine and radiochemistry with the production of shielding systems and equipment for unique applications, for large industrial groups and research organisations, ensuring minimal exposure for the operator, total decontamination and inalterability under any working conditions.

Our strength, Your solutions CrestOptics S.p.A. is a leading company in the development and manufacturing of advanced systems for fluorescence microscopy. Thanks to our strength in R&D and engineering, we specialize in supporting the research community, biotech, and pharma industry with custom solutions tailored for ever-changing demands, paying special attention to customers' needs and scientific applications. Our story Founded in 2011 with a mission to make high-end microscopy technology accessible, we quickly achieved the necessary expertise to build top-tier systems that are indispensable for ground-breaking biological research. In November 2021 Apposite Capital, a specialist international healthcare and life science investor, acquired a majority shareholding in CrestOptics to partner with the management team and employees to accelerate market penetration globally and launch new products. Our products are supported globally by an experienced network of distributors of our branded products and integrated into prestigious and highly complex equipment, through OEM custom design or as a component. Our purpose Through our commitment to excellence, we aim to drive technological innovation in microscopy and to contribute to the advancement of scientific knowledge in various fields, including life sciences, materials research, and biomedical imaging. We have recently taken a significant step towards a more sustainable future by prioritizing the creation of long-term economic, environmental, and social benefits for all stakeholders and generations to come. The application of ESG criteria in our organization's business practices will generate significant value and impact for the scientific community.

We offer whole genome sequencing to help you understand your health, lifestyle, and the risk of inheriting diseases. Simple, clear, and personal reports.

Diasorin is an Italian multinational biotechnology company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics. Starting from 2021, the company also commercializes Life Science products. The Group was founded in 1968 and is headquartered in Saluggia (Italy). Its line of products used by diagnostic laboratories that are part of hospital facilities or operate independently can meet the needs of the following clinical areas: infectious diseases, cardiac markers, bone metabolism, hepatitis and retrovirus, oncology and endocrinology. DiaSorin can offer the market an assay menu that is unique for its width and presence of specialty tests, which identify us as “the” in vitro diagnostics specialist. DiaSorin also provides Life Science products that have a wide range of applications including academic and scientific research, public health and food safety, plant pathogens detection and cell counts, viability, and cell health analyses.

Founded in 2002 in Cartoceto (PU), Italy, Diatheva is a biotechnology company established as a spin-off from the University of Urbino. 70% of all employees holds at least a PhD and oversees all phases of activity, from research and development to production and finishing. For 20 years, Diatheva has been engaged in the research, development, and production of: - biotechnological products: including monoclonal and polyclonal antibodies, antibody fragments, recombinant proteins, recombinant enzymes, and antigens - molecular and immunoenzymatic assays: such as in vitro diagnostics (IVD), veterinary kits, food analysis kits, and environmental kits. To achieve this, Diatheva collaborates with companies, public and private entities, mainly operating in the fields of oncology, microbial infections, and pharmacogenetics. Diatheva operates a cutting-edge GMP production facility authorized by AIFA since 2006 for biomolecules (APIs) and since 2023 for medicinal products.

Dompé farmaceutici is an international biopharmaceutical company involved in all activities of the pharmaceutical value chain, from research to development, production and marketing. As a long-established family company, we blend the stability that comes from our 130-year heritage with the agility and dynamism of a start-up. We can turn transformative breakthroughs into treatments because we have the right qualities and capabilities to deliver new drugs. Our 160,000 square meter R&D and production site in L’Aquila, Italy, is the heart of Dompé. Here, we conduct vital research, and produce and distribute our primary care and biotech products. Primary Care includes a broad spectrum of over-the-counter treatment solutions, prescription medications, supplements and medical devices. Our Biotech focuses on the development of treatments for rare diseases. The main therapeutic areas include pain relief, inflammation, ophthalmology, diabetes care, nutrition and oncology. In the pursuit of improving human health, our R&D strives to break through in unconventional places. This is what led us to Nerve Growth Factor (NGF), a Nobel Prize-winning discovery made in 1986. We leveraged 50 years of research to transform this discovery into a breakthrough treatment. Our human recombinant NGF, cenegermin, is the first treatment for a rare degenerative eye disease, neurotrophic keratitis. That deep appreciation of science keeps us committed to investigating neurotrophins. Our relentless pursuit in identifying new treatments for diseases allowed us to harness the potential of bioinformatics to accelerate the drug discovery process. The result is Exscalate, a structure-based virtual screening platform developed in-house and currently one of the most powerful supercomputing and artificial intelligence platforms for drug testing. We are focused on the road ahead. Our hunger to deliver what patients need from science keeps us focused on what matters. We embrace the challenge in science.

Galileo Research origins lie in 1972 as the Research Centre of Istituto Gentili, an Italian pharmaceutical company founded in 1917. At the beginning of the ‘80s, scientists at the Gentili Research Centre discovered and developed new molecules in the class of bisphosphonates and in the field of bone diseases, in particular clodronate and alendronate. The Research Centre continued to work in the field of bone and joint metabolism and also expanded its knowledge and activities to the areas of oncology and CNS. Galileo Research was established in July 2011.

Intrauma is a medical devices company that specializes in providing healthcare solutions for trauma care through innovative surgical instruments.

We, at iVis Technologies, are considered as the pioneers and innovative thinkers in corneal eye surgery since 1996, the year we launched CIPTA®, our dedicated software for corneal surgery customization, while the majority of refractive surgeries were executed as standard ablations worldwide. Since then, we also considered low invasiveness treatments and patients' wellbeing as the fundamental driving concepts in our R&D activities and thus we developed cTen™, our exclusive no-touch one-step procedure for refractive and therapeutic corneal surgery as the ultimate alternative to LASIK and patient's safety. Nowadays, we are offering the 4D iVis Suite™. the most advanced corneal surgery platform, which includes a comprehensive refractive products portfolio of medical devices. Our iVis Suite™ gives Surgeons the ultimate capability to execute customized refractive treatments correcting wide range of corneal refractive errors with outstanding clinical results and with the lowest possible invasiveness. iVis' R&D activities, along with our mindset for continuous innovation, are the core of our care. Core is Care. Recently, we have introduced the second generation of Precisio™, the world's most advanced High Resolution Tomographer, able to detect the whole anterior corneal segment, incorporating highly detailed epithelial maps and uniquely using a voice driven full automated exam acquisition, for corneal pathology diagnosis and corneal surgery.

Since 1998 LABOMAR and LABOMAR RESEARCH add innovation and technological excellence to your products. LABOMAR is particularly skilled in the manufacturing of Food Supplements, Medical Devices, Foods for Special Medical Purposes, Functional Foods and Cosmetics, most of them derived from internal development and based on innovative patented technologies. Labomar products are a guarantee of safety for Customers and End-users, in compliance with the principles of Good Manufacturing Practice and Quality. In this perspective, Labomar obtained three prestigious certifications: UNI EN ISO 9001:2008, CEI UNI EN ISO 13485:2012 and GMP (Code of Federal Regulation, Title 21, Volume 2, part 111). Visit our website www.labomar.com

Lo.Li. Pharma INTERNATIONAL is a branch of Lo.Li. Pharma Srl, a growing pharmaceutical company, based in Rome, dedicated to the research, development and out-licencing distribution of Medical Devices and Functional Dietary Supplements. The company's key success factor is the continuous effort in developing new products while responding to the needs of patients and of new treatments and prevention tools for the medical class. The innovative formulations of Lo.Li. Pharma have attracted the attention of many foreign Companies and private citizens alike, all looking forward to have Loli's products available in their own countries. With more than 20 products in our portfolio and our brand presented in more than 50 countries, we are always seeking out-licensing opportunities with key strategic partners for long term exclusive distribution. For further information, kindly contact us at info@lolipharmainternational.com or call +39 06.88379670

Mogu is an innovation-driven design company changing the way things are traditionally made. We do this by partnering with our surrounding life-systems. Lead by the principles of Circular Economy and by the certainty that Nature’s intelligence can help us to radically disrupt the design of everyday products, mogu develops mycelium technologies and commercialises innovative products and groundbreaking solutions for everyday use in interiors and architecture. Rooted in growth and cultivation and guided by a strong product-driven approach, mogu products are the result of continuous and iterative R&D on mycelium technology, allowing to deliver responsible and renewable solutions, without compromising performance. Mogu is part of the SQIM technology holding which has the aim of further widening along time the multiple opportunities emerging from R&D activities, and therefore expanding on the true potential of mycelium-based technologies in concretely impacting additional fields and markets, thereby creating a real positive impact in people’s life. Mogu offers today the first commercial mycelium-based products on the market, suitable for interior design applications.

NEXT Genomics è il risultato di un progetto innovativo e di un nuovo modo di fare ricerca. Un punto di contatto tra il mondo accademico e le imprese, un network ad elevata specializzazione mediante il quale fornire soluzioni personalizzate per migliorare la salute di persone, animali e piante; per proteggere l’ambiente e implementare tecnologie, materiali e processi in ambito industriale.

Olon is a global leader in the development and production of active pharmaceutical ingredients (APIs) for CDMO and Generics. We supply more than 300 Active Pharmaceutical Ingredients globally, with one of the most extensive track records in the industry. We provide an integrated package of chemical synthesis and biological processing services which clients can use to manage their drug manufacturing projects fully compliant with regulations. We rely on the broadest technical expertise while maintaining a long-standing quality and reliability Thanks to 2.300 employees and 300 highly experienced and qualified people in R&D team, we are a highly reliable partner. Our global manufacturing networks implies 11 manufacturing sites and 7 R&D departments across the globe, on several decades of experience in supporting pharmaceutical, biotech, food, chemical and bio-industrial companies.

WHO WE ARE PQE Group is a women-owned Contract Quality Organisation and Complete Quality Solution provider for GCP, GLP, GMP, GVP & GDP areas in the Life Science Industry. As an international group of over 2000 employees (40% of whom are female), we are composed of 43 nationalities and have experience working in more than 25 languages. PQE Group has an excellent history of supporting companies of all sizes and exceeding compliance standards from our 40 global offices. We are dedicated to creating value for our customers by putting our multidisciplinary teams and knowledge at their service, allowing our clients to achieve and maintain compliance with the latest regulations, and contributing to creating a safer pharmaceutical environment. WHAT WE DO Since 1998, PQE Group has successfully completed more than 15,000 projects worldwide while serving our 1400+ medical device and pharmaceutical clients. We deliver turnkey quality solutions while focusing on offering exceptional cost-effectiveness and maintaining the highest quality of care for our customers. With our extensive experience, effective project management, and exceptional cost-effectiveness, PQE's solutions are proven to be the winning combination for global corporations of all sizes. WHERE WE'RE GOING We at PQE Group strongly believe that our success is tied to the well-being of the communities and environment around us. We understand that change must come from ourselves first – so we take action through social responsibility goals like sustainable development, gender equality, protection of the environment, and health and safety. PQE Group actively works to achieve our ambitious objectives to foster social change and environmental stability by collaborating with important programs and charity associations around the world.

We make the injection of medicines safer - keeping people safe from infections! Roncadelle Operations is committed to increasing the safety of drug injections and improving the protection of patients and healthcare workers. We are dedicated to reducing the spread of infectious diseases and promoting safer healthcare. Our product portfolio includes a range of patented safety syringes and needle protection systems for pre-filled syringes and cartridges. They are easy to use, offer good value for money and meet current and increasingly stringent regulatory and legal requirements. As a drug delivery device and packaging specialist, we offer value-added services from design to commercialization with scale-up manufacturing solutions. Our services range from customized user-centered design and prototyping to high-quality end-to-end manufacturing solutions. This reflects our commitment to excellence in the healthcare and pharma industry. From the heart of Europe, Roncadelle Operations offers design expertise and state-of-the-art cleanroom production capabilities in proximity to our clients in the pharmaceutical and healthcare industries. We are happy to service your needs! Let's talk.

Founded in 1949, Stevanato Group is one of the world's largest providers of integrated containment and delivery solutions for the biopharmaceutical industry. From the beginning, the Group has developed its own glass forming technology to ensure quality of the highest standards. The Group includes a wide range of skills dedicated to serving the biopharmaceutical and diagnostic industry. It offers glass containers with its historic Ompi brand, plastic components for diagnostics and medical devices, contract manufacturing services for drug delivery systems, up to inspection, assembly and packaging machines. The Group also provides analytical services and tests that study the interaction between container and drug and integration into delivery sys-tems, supporting the drug development process. By bringing together several skills under the same entity, Stevanato Group is able to offer unique solutions to companies by reducing the time to market and the overall cost.

Siamo un'azienda innovativa che opera nel campo dell'immunodiagnostica e della genetica molecolare. Vogliamo essere un punto di riferimento per chi come noi intende contribuire giorno dopo giorno al progresso medico-scientifico. Nei nostri laboratori studiamo soluzioni e prodotti innovativi, garantendo elevati standard qualitativi, competenza e professionalità e avvalendoci dell'esperienza maturata negli anni. Grazie a nuove e sofisticate tecnologie, siamo impegnati in sfide complesse e ambiziose con l'obiettivo di proporre soluzioni diagnostiche sempre più efficienti ed efficaci. Seguici per saperne di più!

Ulisse BioMed is a healthcare biotech company operating in diagnostics, theranostics and therapeutics with the mission to develop innovative solutions in these fields. Ulisse BioMed has three proprietary technology platforms capable of generating innovative and competitive products: Sagitta (molecular diagnostics), NanoHybrid (theranostics and diagnostics) and Aptavir (therapeutics). Ulisse BioMed owns a portfolio of intellectual properties made of 8 international patent applications that cover the three technology platforms (3 related to Sagitta, 2 related to NanoHybrid, 1 related to Aptavir and 2 transversal to the three platforms), two of them are granted in Italy and in Europe.